Bausch + Lomb - BLCO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $19.44
  • Forecasted Upside: 6.54%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$18.25
+0 (0.00%)

This chart shows the closing price for BLCO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bausch + Lomb Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLCO

Analyst Price Target is $19.44
▲ +6.54% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Bausch + Lomb in the last 3 months. The average price target is $19.44, with a high forecast of $22.00 and a low forecast of $17.00. The average price target represents a 6.54% upside from the last price of $18.25.

This chart shows the closing price for BLCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Bausch + Lomb. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/19/2023HC WainwrightBoost Target$19.00 ➝ $22.00Low
5/5/2023HC WainwrightLower Target$21.00 ➝ $19.00Low
5/5/2023BarclaysBoost Target$17.00 ➝ $18.00Low
3/23/2023HC WainwrightReiterated RatingBuy$21.00Low
3/9/2023Needham & Company LLCInitiated CoverageHoldLow
2/24/2023HC WainwrightBoost TargetBuy$20.00 ➝ $21.00Low
2/23/2023Deutsche Bank AktiengesellschaftBoost Target$16.00 ➝ $18.00Low
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$15.00 ➝ $17.00Low
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$20.00Low
2/23/2023Morgan StanleyBoost TargetEqual Weight$18.00 ➝ $20.00Low
2/15/2023Royal Bank of CanadaBoost TargetOutperform$17.00 ➝ $20.00Low
2/2/2023HC WainwrightReiterated RatingBuy$20.00Low
12/21/2022BarclaysInitiated CoverageEqual Weight$17.00Low
11/23/2022The Goldman Sachs GroupLower TargetNeutral$19.00 ➝ $17.00Low
11/3/2022Royal Bank of CanadaLower TargetOutperform$18.00 ➝ $17.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$16.00 ➝ $15.00Low
11/3/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $18.00Low
11/3/2022HC WainwrightLower TargetBuy$21.00 ➝ $20.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00Low
9/12/2022HC WainwrightInitiated CoverageBuy$21.00Low
8/30/2022The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$22.00 ➝ $19.00Low
8/16/2022The Goldman Sachs GroupLower TargetNeutral$22.00 ➝ $19.00Low
7/31/2022Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $18.00Low
7/26/2022Royal Bank of CanadaReiterated RatingInitiatesLow
7/25/2022Royal Bank of CanadaInitiated CoverageOutperform$22.00Low
6/24/2022Evercore ISIInitiated CoverageOutperform$21.00Low
6/9/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $20.00Medium
6/6/2022CitigroupInitiated CoverageBuy$22.00High
5/31/2022Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$25.00Medium
5/31/2022Bank of AmericaInitiated CoverageBuyMedium
5/31/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$19.00Medium
5/31/2022JPMorgan Chase & Co.Initiated CoverageNeutral$20.00Medium
5/31/2022GuggenheimInitiated CoverageBuy$24.00Medium
5/31/2022Wells Fargo & CompanyInitiated CoverageOverweight$23.00Medium
5/31/2022Morgan StanleyInitiated CoverageEqual Weight$22.00Medium
5/31/2022The Goldman Sachs GroupInitiated CoverageNeutral$22.00Medium
5/11/2022CowenInitiated CoverageOutperform$35.00Medium
5/11/2022CowenInitiated CoverageOutperform$35.00Medium
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/4/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/3/2023
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/2/2023
  • 11 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/4/2023
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/3/2023
  • 10 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/3/2023
  • 5 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/2/2023

Current Sentiment

  • 5 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Bausch + Lomb logo
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Read More

Today's Range

Now: $18.25
Low: $17.93
High: $18.35

50 Day Range

MA: $17.55
Low: $15.91
High: $19.51

52 Week Range

Now: $18.25
Low: $12.20
High: $19.96

Volume

278,859 shs

Average Volume

394,033 shs

Market Capitalization

$6.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch + Lomb?

The following Wall Street analysts have issued research reports on Bausch + Lomb in the last twelve months: Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Royal Bank of Canada, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for BLCO.

What is the current price target for Bausch + Lomb?

9 Wall Street analysts have set twelve-month price targets for Bausch + Lomb in the last year. Their average twelve-month price target is $19.44, suggesting a possible upside of 6.5%. HC Wainwright has the highest price target set, predicting BLCO will reach $22.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $17.00 for Bausch + Lomb in the next year.
View the latest price targets for BLCO.

What is the current consensus analyst rating for Bausch + Lomb?

Bausch + Lomb currently has 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLCO, but not buy more shares or sell existing shares.
View the latest ratings for BLCO.

What other companies compete with Bausch + Lomb?

How do I contact Bausch + Lomb's investor relations team?

The company's listed phone number is 905-695-7700. The official website for Bausch + Lomb is www.bausch.com. Learn More about contacing Bausch + Lomb investor relations.